The Latest Analyst Ratings for Madrigal Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Madrigal Pharmaceuticals (NASDAQ:MDGL) has received mixed analyst ratings in the last quarter, with 1 bullish, 1 somewhat bullish, and 2 indifferent ratings. The average 12-month price target for the company is $267.25, representing a 23.64% decrease from the previous average price target of $350.00.
September 11, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Mixed analyst ratings and a decreased price target could lead to uncertainty among investors, potentially impacting Madrigal Pharmaceuticals' stock price.
Analyst ratings can significantly influence investor sentiment. The mixed ratings for Madrigal Pharmaceuticals, coupled with a decreased price target, could lead to uncertainty among investors. This could potentially impact the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100